FIG 6.

Inhibition of KSHV progeny production by FDA-approved tyrosine kinase inhibitors. BJAB-rKSHV.219 (A), HuARLT-rKSHV.219 (B), and Vero-rKSHV.219 (C) cells were used to estimate the inhibitory effect of several FDA-approved kinase inhibitors on KSHV lytic replication. Supernatants from reactivated, inhibitor-treated cells were used to infect HEK293 cells, and the GFP signal in HEK293 cells was measured with a luminometer 48 h after infection. Data obtained from treatments with 0.3 μM, 1 μM, 3 μM, and 10 μM (A) and 0.1 μM, 1 μM, and 10 μM (B and C) concentrations of the mentioned compounds were normalized to that with DMSO. Background signal was estimated by the signal obtained from uninduced cells (UI). Foscarnet (Fos) was used as a positive control at 200 μM. Cell toxicity was assessed by an MTT assay (BJAB-rKSHV.219) or DAPI staining (HuARLT-rKSHV.219, Vero-rKSHV.219). See Table 1 for the complete names of the inhibitors. Bars and error bars represent means ± SD across quadruplicate (A), triplicate (B) results and two datasets, each performed in triplicate (C).